Sugi Predict

Sugi Predict / Targets / PRKCQ

PRKCQ

Protein kinase C theta type · Q04759 · PRKCQ on Sugi Atlas →

147,720 patent compounds predicted against PRKCQ, 103,577 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Staurosporine Staurosporine (SCHEMBL8156) 1.00 15/20
Staurosporine Staurosporine (SCHEMBL8157) 1.00 15/20
SCHEMBL117745 SCHEMBL117745 0.56 7/20
SCHEMBL111482 SCHEMBL111482 0.37 7/20
SCHEMBL109616 SCHEMBL109616 0.34 7/20
SCHEMBL115053 SCHEMBL115053 0.56 6/20
SCHEMBL110075 SCHEMBL110075 0.36 6/20
SCHEMBL112523 SCHEMBL112523 0.34 6/20
Fasudil Fasudil (SCHEMBL4674) 1.00 5/20
Phorbol Myristate Acetate Phorbol Myristate Acetate (SCHEMBL115567) 1.00 5/20
SCHEMBL9306 SCHEMBL9306 0.89 5/20
SCHEMBL78989 SCHEMBL78989 0.62 5/20
Phorbol Phorbol (SCHEMBL72895) 0.62 5/20
SCHEMBL9305 SCHEMBL9305 0.74 4/20
SCHEMBL82376 SCHEMBL82376 0.63 4/20
Phorbol Phorbol (SCHEMBL64353) 0.62 4/20
Phorbol Phorbol (SCHEMBL14937) 0.60 4/20
Daph Daph (SCHEMBL11017) 1.00 3/20
Balanol Balanol (SCHEMBL62128) 1.00 3/20
Balanol Balanol (SCHEMBL62129) 1.00 3/20

Clinical trials — most relevant to PRKCQ by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity PHASE4COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3ACTIVE_NOT_RECRUITING
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
PKC412 and 5-Azacytidine PHASE1/PHASE2COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer PHASE1WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases. nanNOT_YET_RECRUITING
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH nanCOMPLETED
Free Fatty Acid Induced Insulin Resistance nanCOMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome nanCOMPLETED
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Ischemic Preconditioning to Prevent Acute Kidney Injury nanCOMPLETED
Effect of Esterogen Receptor Modulator on Gene in Bipolar Diseas nanNOT_YET_RECRUITING
Molecular Markers of Human Sperm Function nanWITHDRAWN
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Fat Induced Insulin Resistance and Atherosclerosis nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome nanUNKNOWN
NASH AMPK Exercise Dosing (AMPED) Trial nanRECRUITING
Glucagon Like Peptide-1 in Remote Ischemic Conditioning nanCOMPLETED
Effect of Age on Glucose and Lipid Metabolism nanCOMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PRKCQ binder may also engage these)

ProteinNameSimilarity
Q02111 — 1.000 Q02111 →
P09215 — 1.000 P09215 →
Q9WTQ0 — 1.000 Q9WTQ0 →
PRKCD Protein kinase C delta type 1.000 landscape →
Q5PU49 — 0.998 Q5PU49 →
P13678 — 0.993 P13678 →
O19111 — 0.992 O19111 →
STK32A Serine/threonine-protein kinase 32A 0.992 landscape →
Q5R4K9 — 0.991 Q5R4K9 →
P28867 — 0.991 P28867 →
Q62074 — 0.991 Q62074 →
Q6PFQ0 — 0.991 Q6PFQ0 →
Q16975 — 0.991 Q16975 →
Q90XF2 — 0.990 Q90XF2 →
Q9JJX8 — 0.990 Q9JJX8 →
P34722 — 0.990 P34722 →
P34885 — 0.990 P34885 →
F1M7Y5 — 0.990 F1M7Y5 →
PRKCE Protein kinase C epsilon type 0.990 landscape →
P13677 — 0.989 P13677 →
Q02956 — 0.989 Q02956 →
Q8BRK8 — 0.988 Q8BRK8 →
A8XWC4 — 0.988 A8XWC4 →
PRKCZ Protein kinase C zeta type 0.988 landscape →
Q19266 — 0.988 Q19266 →
Q39030 — 0.988 Q39030 →
P09216 — 0.988 P09216 →
P10830 — 0.987 P10830 →
Q12706 — 0.987 Q12706 →
Q852Q2 — 0.987 Q852Q2 →